This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rite Aid Gets Profit Boost From Growing Pharmacy Same-Store Sales

NEW YORK (TheStreet) -- Shares of Rite Aid are climbing on Thursday after the drugstore chain reported higher-than-expected profit for the fourth quarter on growing pharmacy same-store sales and issued a 2015 earnings forecast above analysts' estimates.

VIDEO TRANSCRIPT:

Shares of Rite Aid (RAD) are climbing on Thursday after the drugstore chain reported higher-than-expected profit for the fourth quarter and issued a 2015 earnings forecast above analysts' estimates.

Excluding items, the company earned 10 cents a share in the quarter on revenue of $6.6 billion on growing pharmacy same-store sales.  Analysts were expecting a profit of 4 cents a share on revenue of about $6.5 billion, according to Thomson Reuters.  Looking forward, Rite Aid forecast full-year 2015 earnings of 31 cents to 42 cents a share on sales of $26 billion to $26.5 billion, beating analysts' forecasts of profit of 35 cents a share on revenue of about $25.7 billion.

WATCH: More videos from Brittany Umar on TheStreet TV

The company said it expects its pharmacy sourcing deal with McKesson as well as new and higher-priced generic drugs to drive sales in 2015. Rite Aid also announced that it acquired Texas clinic operator RediClinic, but did not disclose details of the transaction.

At last check, shares of Rite Aid were climbing more than 14% to $7.32.

In New York, I'm Brittany Umar for TheStreet.

Written by Brittany Umar in New York.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $113.29 0.00%
FB $91.01 0.00%
GOOG $630.38 0.00%
TSLA $248.48 0.00%
YHOO $33.14 0.00%

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs